Myleran Oral Tablet 2Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Myleran: Oral tablet (2mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_3334.JPG
Myleran 2mg Tab
Prasco Laboratories
Pill Identification: GX EF3  |  M

What is this Medicine?

BUSULFAN (byoo SUL fan) is a chemotherapy drug. It is used to treat chronic myelogenous leukemia.

In-Depth Information
Select a Medication

Myleran 2mg Tablet

NDC: 763880713
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Chronic Myelogenous Leukemia (CML)

Sometimes used for but not FDA approved for the following conditions:
Stem Cell Transplant Preparation

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Myleran 2mg Tablet

Reported Side Effects for Myleran 2mg Tablet

Cataracts Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
<51.0%*
Severity: MILD
Onset: DELAYED
Yellow Skin Incidence:
<12.0%*
Severity: MODERATE
Onset: DELAYED
Porphyria Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
<100.0%*
Severity: MILD
Onset: EARLY
Unable To Sweat Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Blistery Rash Incidence:
<10.0%*
Severity: MODERATE
Onset: EARLY
Inflammation Of The Lip Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Gynecomastia Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Death Of Liver Tissue Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Rash With Pustules Incidence:
<8.0%*
Severity: MILD
Onset: EARLY
Muscle Weakness Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Pancytopenia Incidence:
<100.0%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
<57.0%*
Severity: MILD
Onset: EARLY
Vesicular Rash Incidence:
<10.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
<7.0%*
Severity: SEVERE
Onset: EARLY
Anemia Incidence:
<69.0%*
Severity: MODERATE
Onset: DELAYED
Decreased Appetite Incidence:
<21.0%*
Severity: SEVERE
Onset: DELAYED
Aplastic Anemia Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Constipation Incidence:
<38.0%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
<28.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
<5.0%*
Severity: SEVERE
Onset: EARLY
Erythema Multiforme Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
High Bilirubin Level Incidence:
<30.0%*
Severity: SEVERE
Onset: DELAYED
Hair Loss Incidence:
<17.0%*
Severity: MILD
Onset: DELAYED
Low White Blood Cells Incidence:
<100.0%*
Severity: MODERATE
Onset: DELAYED
Pulmonary Fibrosis Incidence:
<16.9%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
<26.0%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
<100.0%*
Severity: MODERATE
Onset: DELAYED
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Dry Skin Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Dry Mouth Incidence:
<26.0%*
Severity: MILD
Onset: EARLY
Convulsions Incidence:
2.0-6.0%*
Severity: SEVERE
Onset: DELAYED
Fluid Around The Heart Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Darkened Skin Patches Incidence:
5.0-10.0%*
Severity: MILD
Onset: DELAYED
Painful Bloody Urine Incidence:
7.0-24.0%*
Severity: SEVERE
Onset: DELAYED
Veno-occlusive Disease (VOD) Incidence:
7.7-12.0%*
Severity: SEVERE
Onset: DELAYED
Sinusoidal Obstruction Syndrome (SOS) Incidence:
7.7-12.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cell Counts Incidence:
>10.0%*
Severity: MODERATE
Onset: DELAYED
Low Potassium Levels Incidence:
>62.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Myleran

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5